AHA Acute Coronary Syndromes GUIDELINES Apps and Pocket Guides brought to you courtesy of Guideline Central. Enjoy!
Issue link: https://eguideline.guidelinecentral.com/i/589485
15 Table 11. Myocardial Revascularization (cont'd) Recommendations COR LOE In patients receiving a stent (bare-metal stent or DES) during PCI for NSTE-ACS, P2Y 12 inhibitor therapy should be given for ≥12 months. Options include: • Clopidogrel: 75 mg daily or • Prasugrel: a 10 mg daily or • Ticagrelor: b 90 mg twice daily I B It is reasonable to choose ticagrelor over clopidogrel for P2Y 12 inhibition treatment in patients with NSTE-ACS treated with an early invasive strateg y and/or coronary stenting. IIa B It is reasonable to choose prasugrel over clopidogrel for P2Y 12 treatment in patients with NSTE-ACS who undergo PCI who are not at high risk of bleeding complications. IIa B In patients with NSTE-ACS and high-risk features (e.g., elevated troponin) treated with UFH and adequately pretreated with clopidogrel, it is reasonable to administer a GPI (abciximab, double- bolus eptifibatide, or high-dose bolus tirofiban) at the time of PCI. IIa B Aer PCI, it is reasonable to use 81 mg per day of ASA in preference to higher maintenance doses. IIa B If the risk of morbidity from bleeding outweighs the anticipated benefit of a recommended duration of P2Y 12 inhibitor therapy aer stent implantation, earlier discontinuation (e.g., <12 months) of P2Y 12 inhibitor therapy is reasonable. IIa C Continuation of DAPT beyond 12 months may be considered in patients undergoing stent implantation. IIb C Prasugrel should NOT be administered to patients with a prior history of stroke or transient ischemic attack. III: Harm B PCI—GPIs In patients with NSTE-ACS and high-risk features (e.g., elevated troponin) and not adequately pretreated with clopidogrel or ticagrelor, it is useful to administer a GPI (abciximab, double-bolus eptifibatide, or high-dose bolus tirofiban) at the time of PCI. I A In patients with NSTE-ACS and high-risk features (e.g., elevated troponin) treated with UFH and adequately pretreated with clopidogrel, it is reasonable to administer a GPI (abciximab, double- bolus eptifibatide, or high-dose bolus tirofiban) at the time of PCI. IIa B Anticoagulant therapy in patients undergoing PCI An anticoagulant should be administered to patients with NSTE- ACS undergoing PCI to reduce the risk of intracoronary and catheter thrombus formation. I C Intravenous UFH is useful in patients with NSTE-ACS undergoing PCI. I C a Patients should receive a loading dose of prasugrel provided that they were not pretreated with another P2Y 12 receptor inhibitor. b e recommended maintenance dose of ASA to be used with ticagrelor is 81 mg daily.